

# TUBB4B variants specifically impact ciliary function, causing a ciliopathic spectrum.

Sabrina Mechaussier<sup>1,\*</sup>, Daniel O Dodd<sup>2,\*</sup>, Patricia L Yeyati<sup>2</sup>, Fraser McPhie<sup>2</sup>, Thomas Attard<sup>3</sup>, Amelia Shoemark<sup>4,5</sup>, Deepesh K Gupta<sup>6</sup>, Maimoona A Zariwala<sup>7</sup>, Marie Legendre<sup>8,9</sup>, Diana Bracht<sup>10</sup>, Julia Wallmeier<sup>10</sup>, Miao Gui<sup>11</sup>, Jacob R Anderson<sup>11</sup>, Mahmoud R Fassad<sup>12,13</sup>, David A Parry<sup>2</sup>, Peter A Tennant<sup>2</sup>, Alison Meynert<sup>2</sup>, Gabrielle Wheway<sup>14</sup>, Lucas Fares-Taie<sup>1</sup>, Holly A Black<sup>15,16</sup>, Rana Mitri-Frangieh<sup>17,18</sup>, Catherine Faucon<sup>17</sup>, Josseline Kaplan<sup>1</sup>, Mitali Patel<sup>12,19</sup>, Lisa McKie<sup>2</sup>, Roly Megaw<sup>2</sup>, Christos Gatsogiannis<sup>20</sup>, Mai A Mohamed<sup>12,21</sup>, Stuart Aitken<sup>2</sup>, Philippe Gautier<sup>2</sup>, Finn R Reinholdt<sup>22</sup>, Robert A Hirst<sup>23</sup>, Chris O'Callaghan<sup>23</sup>, Ketil Heimdal<sup>24</sup>, Mathieu Bottier<sup>4</sup>, Estelle Escudier<sup>9,17</sup>, Suzanne Crowley<sup>25</sup>, Maria Descartes<sup>26</sup>, Ethylin W Jabs<sup>27</sup>, Priti Kenia<sup>28</sup>, Jeanne Amiel<sup>29,30</sup>, Ulrike Blümlein<sup>31</sup>, Andrew Rogers<sup>5</sup>, Jennifer A Wambach<sup>6</sup>, Daniel J Wegner<sup>6</sup>, Anne B Fulton<sup>32</sup>, Margaret Kenna<sup>33</sup>, Margaret Rosenfeld<sup>34</sup>, Ingrid A Holm<sup>35,38</sup>, Alan Quigley<sup>36</sup>, Diana M Cassidy<sup>4</sup>, Alex von Kriegsheim<sup>37</sup>, Scottish Genomes Partnership<sup>15</sup>, Genomics England Research Consortium<sup>39</sup>, Undiagnosed Diseases Network<sup>40</sup>, Jean-Francois Papon<sup>41</sup>, Laurent Pasquier<sup>42</sup>, Marlène S Murriss<sup>43</sup>, James D Chalmers<sup>4</sup>, Clare Hogg<sup>5</sup>, Kenneth Macleod<sup>44,45</sup>, Don S Urquhart<sup>44,45</sup>, Stefan Unger<sup>44,45</sup>, Timothy J Aitman<sup>15</sup>, Serge Amselem<sup>8,9</sup>, Jean-Michel Rozet<sup>1</sup>, Serge Amselem<sup>8,9</sup>, Margaret W Leigh<sup>46</sup>, Michael R. Knowles<sup>47</sup>, Heymut Omran<sup>10</sup>, Hannah M Mitchison<sup>12</sup>, Alan Brown<sup>11</sup>, Joseph A Marsh<sup>2</sup>, Julie P I Welburn<sup>3</sup>, Amjad Horani<sup>6,48</sup>, Jean-Michel Rozet<sup>1</sup>, Isabelle Perrault<sup>1,✉</sup>, and Pleasantine Mill<sup>2,✉</sup>

<sup>1</sup>Laboratory of Genetics in Ophthalmology, INSERM UMR 1163, Institute of Genetic Diseases, Imagine, Paris University, Paris, France, 75015

<sup>2</sup>MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, EH4 2XU

<sup>3</sup>Wellcome Trust Centre for Cell Biology, School of Biological Sciences, University of Edinburgh, Edinburgh, UK, EH9 3BF

<sup>4</sup>Respiratory Research Group, Molecular and Cellular Medicine, University of Dundee, Dundee, UK, DD1 9SY

<sup>5</sup>Royal Brompton Hospital, London, UK, SW3 6NP

<sup>6</sup>Department of Pediatrics, Washington University School of Medicine, St. Louis, MO, USA, 63110

<sup>7</sup>Department of Pathology and Laboratory Medicine, Marsico Lung Institute, University of North Carolina at Chapel Hill, NC, USA, 2759

<sup>8</sup>Molecular Genetics Laboratory, Sorbonne Université, Assistance Publique - Hôpitaux de Paris (AP-HP), Hôpital Armand Trousseau, Paris, France, 75012

<sup>9</sup>Sorbonne Université, INSERM, Childhood Genetic Disorders, Paris, France, 75012

<sup>10</sup>Department of General Pediatrics, University Children's Hospital Münster, Münster, Germany, 48149

<sup>11</sup>Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA, 02115

<sup>12</sup>Genetics and Genomic Medicine Department, UCL Institute of Child Health, University College London, UK, WC1N 1EH

<sup>13</sup>Department of Human Genetics, Medical Research Institute, Alexandria University, Alexandria, Egypt,

<sup>14</sup>Faculty of Medicine, University of Southampton, Southampton, UK, SO17 1BJ

<sup>15</sup>Centre for Genomic and Experimental Medicine, MRC Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, EH4 2XU

<sup>16</sup>South East of Scotland Genetics Service, Western General Hospital, Edinburgh, UK, EH4 2XU

<sup>17</sup>Department of Anatomy, Cytology and Pathology, Hôpital Intercommunal de Créteil, Créteil, France, 94000

<sup>18</sup>Biomechanics and Respiratory Apparatus, IMRB, U955 INSERM – Université Paris Est Créteil, CNRS ERL 7000, Créteil, France, 94010

<sup>19</sup>MRC Prion Unit at UCL, UCL Institute of Prion Diseases, London, UK, W1W 7FF

<sup>20</sup>Center for Soft Nanoscience and Institute of Medical Physics and Biophysics, Münster, Germany, D-48149

<sup>21</sup>Biochemistry Division, Chemistry Department, Faculty of Science, Zagazig University, Ash Sharqiyah, Egypt

<sup>22</sup>Core Facility for Electron Microscopy, Department of Pathology, Oslo University Hospital-Rikshospitalet, Oslo, Norway, 20 0372

<sup>23</sup>Centre for PCD Diagnosis and Research, Department of Respiratory Sciences, University of Leicester, UK

<sup>24</sup>Department of Medical Genetics, Oslo University Hospital, Oslo, Norway, 0450

<sup>25</sup>Paediatric Department of Allergy and Lung Diseases, Oslo University Hospital, Oslo, Norway, 0450

<sup>26</sup>Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA, 35233

<sup>27</sup>Icahn School of Medicine at Mount Sinai, New York, NY, USA, 10029

<sup>28</sup>Department of Paediatric Respiratory Medicine, Birmingham Women's and Children's Hospital NHS Foundation Trust, Birmingham, UK

<sup>29</sup>Département de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris (AP-HP), Paris, France, 75015

<sup>30</sup>Laboratory of Embryology and Genetics of Human Malformations, INSERM UMR 1163, Institut Imagine, Université de Paris, Paris, France, 75015

<sup>31</sup>Carl-Thiem-Klinikum Cottbus, Cottbus, Germany, 03048

<sup>32</sup>Department of Ophthalmology, Boston Children's Hospital, Boston, MA, USA, 02115

<sup>33</sup>Department of Otolaryngology, Boston Children's Hospital, Boston, MA, USA, 02115

<sup>34</sup>Department of Pediatrics, University of Washington School of Medicine and Seattle Children's Research Institute, Seattle, WA, USA

<sup>35</sup>Division of Genetics and Genomics and the Manton Center for Orphan Diseases Research, Boston Children's Hospital, Boston, MA, USA

<sup>36</sup>Department of Paediatric Radiology, Royal Hospital for Children and Young People, Edinburgh, UK, EH16 4TJ

<sup>37</sup>Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK, EH4 2XU

<sup>38</sup>Department of Pediatrics, Harvard Medical School, Boston, MA, USA

<sup>39</sup>Genomics England, London, UK, William Harvey Research Institute, Queen Mary University of London, London, UK, EC1M 6BQ

<sup>40</sup>Undiagnosed Diseases Network Coordinating Center, Harvard Medical School, Boston, MA, USA

<sup>41</sup>ENT Department, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris-Saclay University, Le Kremlin-Bicêtre, France, 94270

<sup>42</sup>Medical Genetics Department, CHU Pontchaillou, Rennes, France

<sup>43</sup>Department of Pulmonology, Transplantation, and Cystic Fibrosis Centre, Larrey Hospital, Toulouse, France

<sup>44</sup>Department of Paediatric Respiratory and Sleep Medicine, Royal Hospital for Children and Young People, Edinburgh, UK, EH16 4TJ

<sup>45</sup>Department of Child Life and Health, University of Edinburgh, Edinburgh, UK, EH16 4TJ

<sup>46</sup>Department of Pediatrics, Marsico Lung Institute, University of North Carolina at Chapel Hill, NC, USA, 27599-7020

<sup>47</sup>Department of Medicine, Marsico Lung Institute, University of North Carolina at Chapel Hill, NC, USA, 27599-7020

<sup>48</sup>Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA, 63110

\*These authors contributed equally to this work

tubulin | cilia | primary ciliary dyskinesia | ciliopathies | tubulinopathies | axonemes | centrioles | cytoskeleton | disease modelling | microtubules

Correspondence: [isabelle.perrault@inserm.fr](mailto:isabelle.perrault@inserm.fr), [pleasantine.mill@ed.ac.uk](mailto:pleasantine.mill@ed.ac.uk)

Case number	Samples recruited	Sex	Age range at diagnosis	Primary Ciliary Dyskinesia (PCD)											Sensorineuronal disease (SND)		Mutation		
				Ciliary ultrastructure	Cilia motility	nNO (ppb)	Current FEV1 (% predicted)	NRD	Chronic wet cough	Regular IV antibiotics	Recurrent infections	Rhinosinusitis	Bronchiectasis	Recurrent ear infection	Hydrocephaly	Auditory Defects	ERG	HGV5 protein	
P1	Trio	F	11-15	Ciliary agenesis	Abnormal	15.5	47	YES	YES	YES	YES	YES	YES	YES	NO	YES	CHL	Normal	p.P259L
P2	Trio	F	0-5	Ciliary agenesis	NA	50	107	YES	YES	NO	YES	YES	YES	NO	NO	SNHL/CHL	NA		
P3	Trio	F	0-5	Ciliary agenesis	NA	NA	NA	YES	YES	NA	YES	YES	NA	YES	YES	Hearing deficit	NA		
P4	Family	M	6-10	Ciliary agenesis	Abnormal	23	76	YES	YES	YES	YES	YES	YES	YES	YES	SNHL/CHL	NA		
P5	Singleton	F	0-5	Ciliary agenesis	NA	35	NA	NO	NA	NA	YES	YES	YES	NO	YES	NA	NA		
P6	Family	F	6-10	Ciliary agenesis	NA	6.9	45	YES	YES	YES	YES	NA	YES	YES	YES	CHL	NA		
P7	Singleton	M	11-15	NA	NA	NA	NA	YES	NO	YES	YES	NA	YES	YES	NO	SNHL	NA	p.F242_R251dup	
P8	Duo	M	0-5	Ciliary agenesis	Abnormal	6	75	YES	YES	YES	YES	YES	YES	NO	YES	CHL	Normal	p.P259S	
P9	Trio	M	0-5	Ciliary agenesis	Abnormal	6.7	NA	YES	YES	NO	YES	YES	NO	YES	NO	SNHL/CHL	Flat	p.P358S	
P10	Trio	M	11-15	Ciliary agenesis	Abnormal	NA	NA	NA	NA	NA	YES	YES	NA	NA	NA	SNHL	Flat		
P11	Family	M	6-10	NA	NA	NA	NA	YES	NA	NA	NA	NA	NA	YES	NO	SNHL	Flat		

Extended data- Figure 1: Clinical features of *TUBB4B* cohort reported in this study.

Case number	Change (hg38)	HGVS cDNA	HGVS protein	Zygoty	Inheritance Mode	ACMG Criteria	Platform used
P1	chr9:137242994:C:T	c.776C>T	p.P259L	Heterozygous	de novo	PS2-PM2-PM6-PP2-PP3	WGS: Illumina HiSeq X
P2	chr9:137242994:C:T	c.776C>T	p.P259L	Heterozygous	NA	PM2-PP2-PP3	Capture: Agilent SureSelectQXT NGS kit WES: Illumina NextSeq
P3	chr9:137242994:C:T	c.776C>T	p.P259Leu	Heterozygous	de novo	PS2-PM2-PM6-PP2-PP3	Capture: Agilent SureSelect All Exon V.6 WES: Illumina HiSeq2500
P4	chr9:137242994:C:T	c.776C>T	p.P259L	Heterozygous	de novo	PS2-PM2-PM6-PP2-PP3	Capture: Roche MedExome capture WES: Illumina NextSeq
P5	chr9:137242994:C:T	c.776C>T	p.P259L	Heterozygous	NA	PM2-PP2-PP3	Capture: Roche SeqCap EZ Choice capture WES: Illumina MiSeq
P6	chr9:137242994:C:T	c.776C>T	p.P259L	Heterozygous	de novo	PM2-PM6-PP2-PP3	Capture: Roche xGen Exome v1.0 WES: Illumina Novaseq 6000
P7	chr9:137242934:G:GCCTGCGCTCCAGGCCAGCTCAATGCTGA	c.723_752dup	p.F242_R251dup	Heterozygous	NA	PM2-PM4	Capture: Roche xGen Exome v1.0 WES: Illumina Novaseq 6000
P8	chr9:137242993:C:T	c.775C>T	p.P259S	Heterozygous	NA	PM2-PP2-PP3	WGS: Illumina HiSeq 2500
P9	chr9:137243290:C:T	c.1072C>T	p.P358S	Heterozygous	de novo	PS2-PM2-PP2-PP3	WES: GeneDx
P10	chr9:137243290:C:T	c.1072C>T	p.P358S	Heterozygous	de novo	PS2-PM2-PP2-PP3	Capture: Agilent SureSelect All Exon V5 WES: Illumina HiSeq2500 HT
P11	chr9:137243290:C:T	c.1072C>T	p.P358S	Heterozygous	de novo	PS2-PM2-PM6-PP2-PP3	WES: GeneDx WGS: Baylor Genetics

## Extended data- Figure 2: Genetic features of patient variants in *TUBB4B*.


Case numbers	Change (hg38)	HGVS cDNA	HGVS protein	PolyPhen2 HumVar score	SIFT score	Grantham score	$\Delta\Delta G$ subunit (kcal/mol)	$\Delta\Delta G$ full (kcal/mol)	Study
P1-P6	chr9:137242994:C>T	c.776C>T	p.P259L	probably_damaging (0.993)	deleterious_low_confidence(0.02)	moderately conservative (98)	1.44	4.6	This study
P8	chr9:137242993:C>T	c.775C>T	p.P259S	possibly_damaging (0.847)	deleterious_low_confidence(0.01)	moderately conservative (74)	3.14	4.92	
P9-P11	chr9:137243290:C>T	c.1072C>T	p.P358S	possibly_damaging (0.551)	deleterious_low_confidence(0.04)	moderately conservative (74)	2.31	2.22	
Family 1-3	chr9:140137842G>A	c.1172G>A	p.R391H	probably_damaging (0.993)	deleterious (0)	conservative (29)	0.99	3.41	Luscan et al 2017
Family 4	chr9:140137841C>T	c.1171C>T	p.R391C	probably_damaging (0.999)	deleterious (0)	radical (180)	1.5	2.77	


### Extended data- Figure 3: Description of patient variants in *TUBB4B* and predicted pathogenicity.

Standard predictors struggle to predict pathogenicity of tubulin variants accurately. Using structural modelling of variant effects on both the  $\beta$ -tubulin monomer (subunit) and its interaction with  $\alpha$ -tubulin a heterodimer (full) based on the crystal structure, we could demonstrate profound effects on heterodimer formation in PCD-only variants. Here, higher  $\Delta\Delta G$  means the variant is predicted to destabilize the protein and importantly its interactions (full). Interactions, like lateral interactions between subunits not in the structure, are not captured for interfaces affected like p.P358S.

## Extended data- Figure 4: Segregation and location of pathogenic variants in *TUBB4B* identified in unrelated PCD patients.


(a) P1 was recruited as a trio for WGS based genetic diagnosis of PCD (Black et al. 2022 under revision). Expanded analysis however identified a heterozygous *de novo* missense mutation p.P259L (chr9:g.137242994:C>T (hg38)) in *TUBB4B* (NM\_006088.6) that was present only in the patient. Mutation and the *de novo* pattern of segregation of the allele were confirmed by targeted Sanger sequencing. (b) P2 is proband of a family initially screened for 34 PCD genes including *CCNO* and *MCIDAS* by high-throughput sequencing, followed by screening of a UCL Great Ormond Street ICH targeted gene panel of 40 PCD and 400 motile cilia genes. Whilst biallelic mutations in *DNAH9* were identified comprising a splice acceptor mutation (NM\_001372.3:c.7553-3del) and exonic missense mutation (NM\_001372.3:c.12640G>T, p.Gly4214Cys), the cellular phenotype of reduced generation of motile cilia was not in keeping with pathogenic variants in this gene(70). Reanalysis of sequencing data confirmed a heterozygous *TUBB4B* *de novo* missense mutation p.P259L (chr9:137242994:C>T (hg38)) only in the patient, and not present in either parent. (c) P3 is proband from a trio recruited for WES based genetic diagnosis of PCD, followed by targeted analysis of variants in *TUBB4B* (NM\_006088.6) which identified a heterozygous '*de novo*' missense variant [c.776C>T; p.P259L] in exon 4 in the patient that was not present in either parent or a non-related control. (d) P4 is a proband recruited as a family for WES genetic diagnosis of PCD, which identified a heterozygous *de novo* missense mutation p.P259L (g.chr9:137242994:C>T (hg38)) in *TUBB4B*. Mutation confirmation and segregation of the allele were performed by targeted analysis of the *TUBB4B* locus using Sanger sequencing. (e) P5 is proband recruited as a singleton for genetic diagnosis of PCD. After a negative targeted capture sequencing of 50 PCD genes, Sanger sequencing of *TUBB4B* identified a heterozygous missense mutation p.P259L (g.chr9:137242994:C>T (hg38)). Parents were not tested. (f) P6 is patient recruited for whole exome sequencing for genetic diagnosis of PCD, followed by targeted analysis of variants in *TUBB4B* (NM\_006088.6) which identified a heterozygous *de novo* missense variant [c.776C>T; p.P259L] in exon 4. Both the parents were also tested and confirmed to be wild type (WT) at this locus. (g) Summary of variants identified in all patients (P1-P6) as heterozygous for c.776C>T, p.P259L missense variant in exon 4 (below) compared to control sequence (above). Base sequence, amino-acid sequence and codon numbers are shown. Location of base substitution is underlined and amino-acid substitution is depicted in red. (h) WES followed by targeted analysis of variants in *TUBB4B* (NM\_006088.6) identified a heterozygous in-frame 30 bp duplication variant [c.723\_752dup; p.(F242\_R251dup)] in exon 4 in patient P7, that was verified by Sanger sequencing (proband, lower chromatogram, compared to a healthy individual). DNA from the parents of P7 were not available for the segregation analysis.(i) Proband P8 was recruited as a duo for WGS which on analysis identified a heterozygous missense mutation affecting the same residue but different nucleotide from P1-6. Here, p.P259S (chr9:137242993:C>T (hg38)) was identified in *TUBB4B* only in the patient, and was not present in the parent. DNA from the other parent was not available for segregation analysis. (j) Proband P9 in our study, was recruited as part of a family for WES to diagnose profound sensorineuronal disease (SND) including early onset vision and hearing loss, as well as respiratory disease consistent with PCD. A variant c.1072C>T (p.P358S) in exon 4 of the *TUBB4B* gene (NM\_006088.5) was identified in only the patient sample in a heterozygous state, confirming *de novo* inheritance. Results confirmed by Sanger sequencing. (k) Proband P10, recruited with a history of bilateral sensorineural hearing loss, blindness (SND), chronic kidney disease with nephromegaly and hypertension, chronic productive cough and a history of recurrent sinus and ear infections consistent with PCD. A variant c.1072C>T (p.P358S) in exon 4 of *TUBB4B* (NM\_006088.5) was identified in only the patient sample in a heterozygous state, confirming *de novo* inheritance. (l) Patient P11 was recruited with a history of congenital heart disease, specifically restrictive cardiomyopathy, as well as hearing and sight loss (SND), plus PCD features such as severe inner ear infections. WES was performed on the parent, sibling and proband initially, which identified the variant c.1072C>T (p.P358S) in exon 4 of *TUBB4B* (NM\_006088.5). Inheritance was confirmed by Sanger sequencing in the clinical genetics lab on the proband and the other parent's samples, where the presence of the variant in the heterozygous state was detected only in the patient. (m) Summary of variants identified in all patients (P9-P11) as heterozygous for c.1072C>T, p.P358S missense variant in exon 4 (below) compared to control sequence (above). Base sequence, amino-acid sequence and codon numbers are shown. Location of base substitution is underlined and amino-acid substitution is depicted in red. In all pedigrees, males and females are designated by the squares and circles, respectively. Filled symbols represent affected probands. Red arrow above chromatograms highlights the affected residue.





### Extended data- Figure 5: *TUBB4B* variants affect ciliary number, length and microtubule PTMs.


(a-j')TEM of nasal brush epithelial cells from control (a,b) and PCD patients with p.P259L variant (P3, c-i') or p.P259S (P8, j,j'). In control cells, dense, long cilia on the surface(a,b), which in cross-section clearly transition through docked basal body (MTDs), transition to MTDs exiting the cell with characteristic Y-links of transition zone and then to '9+2' MTDs of the axoneme. In PCD patient cells evidence of disrupted centriole assembly and amplification is observed including misoriented and internally docked centrioles without axonemes as well as partial structures (c-f). Dashed magenta ROI in (c) with increased zoom to highlight features (c'). (g-i') P3 TEM shows rare short cilia without clear axonemal microtubules (g,h) or dilated cilia tips with disorganized microtubules and granular material (i,i'). (j,j') P8 TEM of short cilia with bulbous head shows splayed microtubules within the expanded tip. (k) Nasal brush epithelial cells were cultured and differentiated in ALI from healthy parent (CTL) and syndromic PCD (P9) patient (lower) before sectioning for immunofluorescence confirming reduced centrioles (FOP: magenta) and loss of axonemes, with abnormal acetylated ( $\alpha$ -tubulin staining (green) mislocalizing within the cytoplasm. (l,m) Immunofluorescence of healthy donor (CTL) or patient (P1) nasal brushings stained for (l) cilia outer and inner dynein arm motors (DNAI2: cyan; DNALI1: yellow) of the IFT-B complex (IFT88: magenta;) and (m) microtubule post-translational modifications ( $\alpha$ -tubulin: yellow; polyglutamylated tubulin: magenta; detyrosinated tubulin: cyan). Scale bars represent: 10  $\mu$ m (k-m), 1  $\mu$ m (c,f), 500 nm (j, f), 250 nm (c'-e, g, i'), and 100 nm (j).



## Extended data- Figure 6: Generation of *Tubb4b* knock-out mice support a dominant negative mechanism of disease for patient pathogenic variants *in vivo* as haploinsufficiency for *Tubb4b* has no effect.


(a-c) Two independent deletion alleles were generated by Cas9 genome editing in the 4th exon of *Tubb4b* and founder screening. Both alleles cause a frame shift and premature termination codon. (c) Both alleles are protein null for TUBB4B unique peptides by mass spectrometry (shown for KO2). (d-f) *Tubb4b*<sup>-/-</sup> primary cilia on fibroblasts show no difference in percentage ciliation (d), cilia length (e) or gross structure by immunofluorescence (f). (g-i) Despite the pronounced hydrocephaly phenotypes visible *in vivo*, mutant primary ependymal cells differentiated *in vitro* show no difference by high-speed video microscopy in percentage of cells with coordinated beating (g), ciliary beat frequency (h) or quantification of cilia structures stained for immunofluorescence (i). (j) Whole-mount immunofluorescence of oviducts reveals a similar arrest of ciliogenesis as in airway epithelia. (k-n) Heterozygous KO animals (shown for KO2) are phenotypically normal, showing normal trachea cilia numbers (k) and lengths (l), normal fertility, as shown by normal spermatogenesis (m), and postnatal survival/growth (n). (o) Single cell RNASeq heatmaps show the proportions of cells expressing each α- and β-tubulin isotype (RNA count greater than zero) in each cell type identified in the population from published mouse lung (magenta)(68), ependymal (blue)(66) and choroid plexus (black)(67) single cell RNASeq datasets. Rows are clustered on similarity of proportions among cell types (scale 0-1). Cilia length and number of ciliated cells in fibroblasts were quantified using ARL13B as a marker, N = 3 biological replicates per genotype with (h) n > 139 cells per biological replicate and (i) n > 87 cells per biological replicate, mean values are plotted. Ependymal beat coordination and beat (k, l) were calculated from N = 3 biological replicates per genotype, n > 17 cilia measurements per replicate. (j, m, n) Fibroblast Growth Factor Receptor 1 Oncogene Partner (FOP): yellow, acetylated α-tubulin: magenta, actin: cyan (m) or ARL13B: cyan (j). Scale bars represent: 250 μm (m), 25 μm (l), 10 μm (i, j) and 5 μm (f). (c, k, n) Graphic bars represent the mean ± SEM derived from N=4 biological replicates (c), N=3 biological replicates, n>18 cells/sample (k) and N= 155 animals. (d, e, g, h) Statistical analyses were carried out by the PLSD Fisher test. Graphic bars represent the mean ± SEM derived from three biological replicates. Student's t-test: ns, not significant; \*\*, p ≤ 0.01.






### Extended data- Figure 7: Disease-causing TUBB4B variants alter microtubule dynamics.

Microtubule network dynamics analysis of RPE1 cells overexpressing TUBB4B variants, showing immunostaining of FLAG-tagged TUBB4B (green) and EB1 (magenta) protein upon cold-induced depolymerization (20 and 30 minutes) and repolymerization at 37 °C (4 and 6 minutes). See **Figure 3(g, h)** for quantification of repolymerization. Scale bars represent: 10  $\mu\text{m}$ .



## Extended data- Figure 8: *TUBB4B* variants cause dominant negative disease through distinct molecular mechanisms affecting heterodimerization or polymerization.

(a) Immunoblot of *in vitro* translated ALFA-tagged control and *TUBB4B* patient variants. All PCD-only (p.P259L, p.P259S, Dup) and syndromic PCD+SND p.P358S *TUBB4B* variants are stable. (b) Schematic of tubulin heterodimer assembly pathway. Binding of partially folded tubulin molecules as they emerge from the ribosomes by prefoldin and subsequent folding by the cytoplasmic chaperonin CCT. These quasi-native tubulin intermediates interact with five tubulin-specific chaperones named tubulin cofactors A through E (TBCA–TBCCE). The native assembly-competent tubulin is released from a supercomplex that contains both  $\alpha$ - and  $\beta$ -tubulin and cofactors C–E, upon hydrolysis of GTP by  $\beta$ -tubulin in the supercomplex. (c–i) Effects of *TUBB4B* variants on tubulin stability and heterodimerization were investigated using Sf9 insect cells expressing recombinant bacmids containing human tubulin- $\alpha$ 1A with an internal His tag and human tubulin- $\beta$ 4B-FLAG. The recombinant bacmid also contains a GFP reporter gene to monitor infection of Sf9 cells, and is used as a loading control. (c) Size exclusion chromatography analysis and elution profile for the indicated constructs for porcine  $\alpha/\beta$ -tubulin (red), FLAG-eluted tubulin- $\alpha$ /tubulin- $\beta$ 4B (blue) and FLAG peptide (black) (c, left panel). Coomassie-stained gels showing elution profiles for the corresponding protein complexes (c, right panel). Whole insect cell pellets were analyzed by immunoblot probed with anti-His and anti-FLAG antibodies for  $\alpha$ -tubulin and  $\beta$ -tubulin respectively to monitor expression (p.P259L/S (d); Dup (f); p.P358S (h)), as well as GFP to monitor transduction. After elution from His-tag affinity Ni-NTA beads, immunoblots for recombinant tubulin heterodimers were probed with anti-His and anti-FLAG antibodies for  $\alpha$ -tubulin and  $\beta$ -tubulin respectively to monitor heterodimerization (p.P259L/S (e); Dup (g); p.P358S (i)).



## Extended data- Figure 9: Engineered point mutations in *Tubb4b* do not recapitulate patient phenotypes in the mouse retina.

(a) Strategy to generate LCA KI p.R391H allele by Cas9 genome editing in the 4th exon of *Tubb4b* and Sanger sequencing to validate. (b) *Tubb4b*<sup>R391H/+</sup> animals show no decrease in fitness or survival postnatally. (c-e) *Tubb4b*<sup>R391H/+</sup> animals show no early onset or age-related degeneration of photoreceptors by histology (c) or immunofluorescence (d) (rhodopsin: red; M-opsin: green) in 4 month adult mice. (e) *Tubb4b*<sup>R391H/+</sup> animals show no evidence of physiological changes in neuroretina with age as shown by electroretinogram unlike the p.R391H/+ human patients. (f) Species-specific differences in expression of TUBB4B in the neuroretina are likely to account for these differences. Heatmaps show the proportions of cells expressing each tubulin (RNA count greater than zero) in each cell type identified in the population from published mouse (left)(35) and human (right)(34) neuroretina single cell RNASeq datasets. Rows are clustered on similarity of proportions among cell types

(scale 0-1). Scale bars represent: 100  $\mu\text{m}$  (c) and 10  $\mu\text{m}$  (d). (b, e) Graphic bars represent the mean  $\pm$  SEM derived from N>3 animals per time point.

Name	Sequence	Application	Source
Tubb4b Exon4 p.R391H guide	5'-GAAGGCTTGTCTGGAACATTG-3'	CRISPR guide for generation of Tubb4b <sup>R391H</sup> mouse	GeneArt Precision gRNA synthesis kit (ThermoFisher Scientific, USA)
Tubb4b Exon4 p.R391H patient variant KI ssODN	5'-GAAGGCTTGTCTGGAACATTG-3'	Repair template for generation of Tubb4b <sup>R391H</sup> mouse	
Tubb4b Exon4 p.P259L guide	5'-CCATATTTACAGCCAGTTCCGC-3'	CRISPR guide for generation of Tubb4b <sup>P259L</sup> mouse	GeneArt Precision gRNA synthesis kit (ThermoFisher Scientific, USA)
Tubb4b Exon4 p.P259L patient variant KI ssODN	5'- GCTGGGTGAGCTCAGGAACCTGTCAAGGACAGCTACTGCTGCTGCCCGCTGTCAAGGGGGCAAGCCAGGCATGAAG AAGTGCAGCGGAGGAGGAGGACACATGTTAAcGcCAGTTTCCGcAGGTTCAGATTAGCTGGCCAGGGAATCGCAGGCAAG TGTTACCCCACTCATGTGGCGACACTAGATGGTTC-3'	Repair template for generation of Tubb4b <sup>P259L</sup> mouse	IDT
Tubb4b Exon4 p.P259L patient silent mutation ssODN	5'- GCTGGGTGAGCTCAGGAACCTGTCAAGGACAGCTACTGCTGCTGCCCGCTGTCAAGGGGGCAAGCCAGGCATGAAG AAGTGCAGCGGAGGAGGAGGACACATGTTAAcGcCAGTTTCCGcAGGTTCAGATTAGCTGGCCAGGGAATCGCAGGCAAG TGTTACCCCACTCATGTGGCGACACTAGATGGTTC-3'	Repair template for generation of Tubb4b <sup>Δ</sup> mouse: silent mutation control	IDT
Tubb4b Exon4 p.P259L guide	5'-AAATGCTGACCTGCGGAAC-3'	CRISPR guide for generation of Tubb4b <sup>P259L</sup> mouse	GeneArt Precision gRNA synthesis kit (ThermoFisher Scientific, USA)
Tubb4b Exon4 p.P259L patient variant KI ssODN	5'- CACCCCACTTACGCTGACCTGAACATCTAGTGTCCGCCACAGTGAAGTGGGTAAcCACTTCCCTGCTGATTCCTGGCCAGCTA AATCTGTACTCTCCGAGCTGCTTAAATATGTGCTCTTCCCTGCTGCACTTCTCATGTGGCCAGGGAATCGCAGGCAAG GCGCGGCGAGCAGCAGTACCCTCCCTGACA-3'	Repair template for generation of Tubb4b <sup>P259L</sup> mouse	IDT
Tubb4b Exon4 p.P259S guide	5'-CCATATTTACAGCCAGTTCCGC-3'	CRISPR guide for generation of Tubb4b <sup>P259S</sup> mouse	GeneArt Precision gRNA synthesis kit (ThermoFisher Scientific, USA)
Tubb4b Exon4 p.P259S patient variant KI ssODN	5'- GCTGGGTGAGCTCAGGAACCTGTCAAGGACAGCTACTGCTGCTGCCCGCTGTCAAGGGGGCAAGCCAGGCATGAAG AAGTGCAGCGGAGGAGGAGGACACATGTTAAcGcCAGTTTCCGcAGGTTCAGATTAGCTGGCCAGGGAATCGCAGGCAAG TGTTACCCCACTCATGTGGCGACACTAGATGGTTC-3'	Repair template for generation of Tubb4b <sup>P259S</sup> mouse	IDT
Tubb4b Exon4 p.P259S patient silent mutation ssODN	5'- GCTGGGTGAGCTCAGGAACCTGTCAAGGACAGCTACTGCTGCTGCCCGCTGTCAAGGGGGCAAGCCAGGCATGAAG AAGTGCAGCGGAGGAGGAGGACACATGTTAAcGcCAGTTTCCGcAGGTTCAGATTAGCTGGCCAGGGAATCGCAGGCAAG TGTTACCCCACTCATGTGGCGACACTAGATGGTTC-3'	Repair template for generation of Tubb4b <sup>Δ</sup> mouse: silent mutation control	IDT
Tubb4b Exon4 p.P358S guide	5'-GCCACATTTTCAGCCCGG-3'	CRISPR guide for generation of Tubb4b <sup>P358S</sup> mouse	GeneArt Precision gRNA synthesis kit (ThermoFisher Scientific, USA)
Tubb4b Exon4 p.P358S patient variant KI ssODN	5'- GTGGCAAGATGCTGTGAAGCTCTCTGAGATCGTTTGAACAGCTCTGAATAGCGTGTGCTGCAATGAAGGTGGCCGA CATTTTCAGCCCGGAGATGGAATGTCACAGACAGCTGCTTCACTTGTGGGATCCCACTCAACAAGTAGCTGCTGTTCT GTTTTGACATTAAGCATCTGTTGCTCACCTCC-3'	Repair template for generation of Tubb4b <sup>P358S</sup> mouse	IDT
Tubb4b Exon4 p.P358S patient silent mutation ssODN	5'- GTGGCAAGATGCTGTGAAGCTCTCTGAGATCGTTTGAACAGCTCTGAATAGCGTGTGCTGCAATGAAGGTGGCCGA CATTTTCAGCCCGGAGATGGAATGTCACAGACAGCTGCTTCACTTGTGGGATCCCACTCAACAAGTAGCTGCTGTTCTG TTTTGACATTAAGCATCTGTTGCTCACCTCC-3'	Repair template for generation of Tubb4b <sup>Δ</sup> mouse: silent mutation control	IDT
Tubb4b Exon4 KO guide	5'-CCATATTTACAGCCAGTTCCGC-3'	CRISPR guide for generation of Tubb4b <sup>Δ</sup> mouse, generated while targeting p.P259L and p.P259S mutations	GeneArt Precision gRNA synthesis kit (ThermoFisher Scientific, USA)

Table 4.2 Site mutagenesis and genotyping primers.

Site mutagenesis primers			
Patient variant	Primer name	Primer Sequence	Process
P259L	p.P259L_forward	5' CTGTGAACATGGTCTGTTCCCGGCTGCA 3'	Site directed mutagenesis
	p.P259L_reverse	5' TGCAGCCGGGAAACAGGACCATTGCACAG 3'	
P259S	p.P259S_forward	5' GCTGTGAACATGGTCTGTTCCCGGCTGC 3'	Site directed mutagenesis
	p.P259S_reverse	5' GCAGCCGGGAAACAGGACCATTGCACAGC 3'	
P358S	p.P358S_forward	5' CTGTCTGTGACATCCCATCTCGGGGCTAAAAAT 3'	Site directed mutagenesis
	p.P358S_reverse	5' ATTTTATGCCCCGAGATGGGATGTCACAGACAG 3'	
R391C	p.R391C_forward	5' CACGGCCATGTTCCGGTGAAGGCCTTCCTGCAC 3'	Site directed mutagenesis
	p.R391C_reverse	5' GTGCAGGAAGGCCTTGCA CCGGAACATG GCCGTG 3'	
R391H	p.R391H_forward	5' CACGGCCATGTTCCGGCA CAAAGGCCTTCCTGCAC 3'	Site directed mutagenesis
	p.R391H_reverse	5' GTGCAGGAAGGCCTTGTC CCGAATG GCCCGT 3'	
Genotyping primers			
Mouse Line	Primer name	Primer Sequence	Process
Tubb4b <sup>R391H</sup>	Tubb4b_R391H F	5' CTGAAAATGTCGCCCACT 3'	PCR followed by Sanger sequencing
	Tubb4b_R391H R	5' GACTAAGACAGCTCTAAGCC 3'	
Tubb4b <sup>KO</sup>	Tubb4b KO F	5' GTTGAGCCCTACAATGCCAC 3'	PCR followed by Sanger sequencing
	Tubb4b KO R	5' GAAGTGGCCGACATTTCA 3'	

Extended data- Figure 10: List of guides, repair ssODNs, primers and antibodies used in this study.

**Table 4.3 Primary antibodies**

Antigen	Antibody/Clone Name	Host species	Source	Application
$\alpha$ -tubulin	DM1A	Mouse	Sigma	WB (1:1000); IF (1:2000, MeOH)
$\alpha$ -tubulin	YL1/2, ab6160	Rat	Abcam	WB (1:2000); IF (1:1000, PFA)
Acetylated $\alpha$ -tubulin	6-11B-1, T6793	Mouse	Sigma	IF (1:1000-1:5000)
ALFA-HRP	N1505-HRP	Camelid nanobody	Nanotag	WB (1:1000)
ARL13B	17711-1-AP	Rabbit	ARL13B	IF (1:1000, PFA)
Centrin	20H5 04-1624	Mouse	Merck	IF (1:500, MeOH w. PE or PFA)
Deetyrosinated tubulin	AA12, ab254154	Mouse	Abcam	IF (1:1000, PFA)
DNALI1	HPA028305	Rabbit	Sigma	IF (1:200, PFA)
DNALI1	N-13	Goat	Santa Cruz	IF (1:75, PFA)
DNAH5	HPA035364	Rabbit	Sigma	IF (1:200, PFA)
DNAI2	IC8	Mouse	Abnova	IF (1:100, PFA)
EB1	5/EB1	Mouse	BD Biosciences	IF (1:200, MeOH)
FLAG	ab95045	Goat	Abcam	IF (1:5000, MeOH)
FLAG	M2, F1804	Mouse	Sigma	WB (1:10000)
FOP	11343-1-AP	Rabbit	Proteintech Group	IF (1:500, PFA)
Gamma tubulin	GTU88, T6557	Mouse	Sigma	IF (1:500, MeOH w PE)
GFP	MMS-118P	Mouse	Covance	WB (1:5000)
His	02-10667	Rabbit	RayBiotech	WB (1:1000)
IFT88	13967-1-AP	Rabbit	Proteintech Group	IF (1:100, PFA)
M-OpSin	OSR00222W	Rabbit	ThermoFisher Scientific	IF (1:500, PFA)
Polyglutamylated tubulin	GT335, AG-20B-0020-C100	Mouse	AdipoGen Life Sciences	IF (1:1000, PFA or MeOH)
Pericentrin	ab4448	Rabbit	Abcam	IF (1:1000, MeOH)
Rhodopsin	4D2, NBP2-59690	Mouse	Novus Biologicals	IF (1:500, PFA)
TBCD	14867-1-AP	Rabbit	Proteintech Group	WB (1:1000)

Probes	Cat number	Modification	Source	Application
ActinRed™ 555 ReadyProbes™	R37112	Rhodamine	Thermo Fisher Scientific	IF (2 drops/mL)
Alexa Fluor 647 Phalloidin	A22287	Alexa-647	Thermo Fisher Scientific	IF (1:500)

**Table 4.4 Secondary antibodies**

Antigen	Host Species	Dilution	Source	Application
ECL $\alpha$ -Mouse IgG, HRP-conjugated	Sheep	1:7500	GE Healthcare UK Ltd	WB
ECL $\alpha$ -Rabbit IgG, HRP-conjugated	Sheep	1:7500	GE Healthcare UK Ltd	WB
HRP-conjugated $\alpha$ -Rabbit IgG H + L	Goat	1:5000	BioRad	WB
HRP-conjugated $\alpha$ -Mouse IgG H + L	Goat	1:5000	BioRad	WB
Alexa 488, 568, 594, 647-conjugated $\alpha$ -Mouse	Donkey	1:500	Invitrogen Molecular Probes	IF
Alexa 488, 594, 647 -conjugated $\alpha$ -Rabbit	Donkey	1:500	Invitrogen Molecular Probes	IF
Alexa 555, 647-conjugated $\alpha$ -Goat	Donkey	1:500	Invitrogen Molecular Probes	IF